Patents by Inventor Herren Wu

Herren Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210061906
    Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
    Type: Application
    Filed: May 26, 2020
    Publication date: March 4, 2021
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • Publication number: 20200172625
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Application
    Filed: April 8, 2019
    Publication date: June 4, 2020
    Inventors: ANTHONY COYLE, PETER KIENER, HERREN WU, RICARDO CIBOTTI
  • Publication number: 20200055944
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Application
    Filed: July 15, 2019
    Publication date: February 20, 2020
    Inventors: Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
  • Patent number: 10329345
    Abstract: Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: June 25, 2019
    Assignee: MedImmune Limited
    Inventors: Vahe Bedian, William Dall'Acqua, Herren Wu, Michael Bowen, Jeffrey Brown, Ralph Minter, Andrew Buchanan
  • Patent number: 10301390
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: May 28, 2019
    Assignee: AstraZeneca AB
    Inventors: Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
  • Publication number: 20180273621
    Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
    Type: Application
    Filed: January 5, 2018
    Publication date: September 27, 2018
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • Publication number: 20180244791
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Application
    Filed: May 4, 2018
    Publication date: August 30, 2018
    Inventors: Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
  • Patent number: 9988459
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: June 5, 2018
    Assignee: ASTRAZENECA AB
    Inventors: Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
  • Publication number: 20180118839
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Application
    Filed: September 21, 2017
    Publication date: May 3, 2018
    Inventors: ANTHONY COYLE, PETER KIENER, HERREN WU, RICARDO CIBOTTI
  • Patent number: 9896505
    Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: February 20, 2018
    Assignee: MedImmune, LLC
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • Publication number: 20170183414
    Abstract: Cysteine engineered antibodies useful for the site-specific conjugation to a variety of agents are provided. Methods for the design, preparation, screening, selection and use of such antibodies are also provided.
    Type: Application
    Filed: December 20, 2016
    Publication date: June 29, 2017
    Inventors: Nazzareno Dimasi, Changshou Gao, Herren Wu
  • Publication number: 20170174756
    Abstract: Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.
    Type: Application
    Filed: October 27, 2016
    Publication date: June 22, 2017
    Inventors: VAHE BEDIAN, William DALL'ACQUA, Herren WU, Michael BOWEN, Jeffrey BROWN, Ralph MINTER, Andrew BUCHANAN
  • Publication number: 20170166630
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: July 29, 2016
    Publication date: June 15, 2017
    Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
  • Publication number: 20170101468
    Abstract: The present invention provides human anti-IL-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to IL-6 and that has an extended in vivo half-life for the treatment and prevention of IL-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors.
    Type: Application
    Filed: December 2, 2016
    Publication date: April 13, 2017
    Inventors: Michael Bowen, Herren Wu, William Dall'Acqua, Peter Kiener, Bahija Jallal, Anthony Coyle
  • Patent number: 9567389
    Abstract: The present invention relates to a viral vector encoding for a library of antibodies or antibody fragments that are displayed on the cell membrane when expressed in a cell. The present invention provides cells comprising the viral vector nucleic acids and methods of screening the libraries for antibodies or antibody fragments with desired characteristics.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: February 14, 2017
    Assignee: MedImmune, LLC
    Inventors: Changshou Gao, Herren Wu
  • Publication number: 20160145335
    Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
    Type: Application
    Filed: October 8, 2014
    Publication date: May 26, 2016
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • Publication number: 20160002352
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: July 6, 2015
    Publication date: January 7, 2016
    Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
  • Publication number: 20160002353
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: July 6, 2015
    Publication date: January 7, 2016
    Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
  • Publication number: 20150376295
    Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: July 6, 2015
    Publication date: December 31, 2015
    Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
  • Patent number: 9176129
    Abstract: The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: November 3, 2015
    Assignee: MedImmune, LLC
    Inventors: Herren Wu, Manuel Baca, Jeffrey Swers, Benoy Chacko